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We addressed in this study whether quantifying the extent of disease on bone scans can predict the disease death of patients with
advanced prostate cancer using computer-assisted image analysis. Pretreatment radionuclide bone scans were reviewed in 56
patients with bone metastases from prostate cancer, and the percentage of the positive area on a bone scan (%PABS) was quantified
automatically using a personal computer with the NIH Image program for estimation of the accurate extent of metastatic bone
lesions on a bone scan. The significance of the %PABS as well as the other known prognostic factors was evaluated using univariate
and multivariate Cox proportional hazards analysis. In univariate regression analysis, the %PABS (P¼0.0155), serum alkaline
phosphatase (P¼0.0272), the tumour grade based on biopsy (P¼0.044) and the number of bone lesions on bone scans
(P¼0.0388) were well associated with disease-specific survival. In multivariate analysis, the %PABS (P¼0.0155, relative risk ratio
2.603), but not the other factors, was the independent predictor of the disease death. These results suggest that the %PABS is a novel
parameter for predicting the prognosis of patients with advanced prostatic cancer.
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Bone metastasis is common in advanced prostate cancer and
causes considerable morbidity including pain, pathological frac-
tures and disability. The presence of bone metastasis is of
prognostic importance in prostate cancer, because the extent of
the disease (EOD) on a bone scan significantly affects overall
survival (Soloway et al, 1988; Ernst et al, 1991). Bone scanning
remains the most effective radiological procedure for detecting
bone metastasis with 1% false-negative rate (Schaffer
and Pendergrass, 1976), and for monitoring progression of bone
metastasis. Visual analysis of bone scans is a common method
to estimate the extent of skeletal disease. Several studies
have proposed a grading classification for the bone metastasis
based on the pattern of uptake on the bone scan (Amico et al,
1991; Chybowski et al, 1991) or based on the quantitation of the
number of sites (Soloway et al, 1988; Erdi et al, 1997). However,
quantitative analysis of all bone metastases is a time-consuming
task because patients with advanced prostatic cancer usually
have multiple disease sites. In addition, the assessment of response
and progression largely vary, and thus it is difficult to have
reproductive results in a large population through the conven-
tional assessment. To more accurately determine the amount of
tumour present at baseline and to monitor the tumour’s response
to therapy, we have addressed in this study whether quantifying
the extent of bone metastases and express it as the percentage of
the positive area on a bone scan (%PABS) can predict the disease
death of patients with advanced prostatic cancer.
MATERIALS AND METHODS
Patients
We retrospectively reviewed 56 consecutive patients with prostate
cancer with bone metastasis who visited the Kurume University
Hospital in Japan from March 1994 to March 2000. All patients
were newly diagnosed as histologically confirmed adenocarcinoma
of the prostate, and none of them had previous treatment. Each
patient was evaluated in a standard fashion with a careful history
and physical examination, serum PSA determination, transrectal
ultrasonography and radionuclide bone scan. All patients under-
went computerised tomography (CT) or magnetic resonance
imaging scan (MRI) of the pelvis. Serum samples were obtained
and stored at  201C. Serum PSA levels were determined using
Tandem-R (Hybritech Inc., San Diego, CA, USA) assay with a
normal range between 0 and 4.0ngml
 1. The serum levels of
pyridinoline crosslinked carboxyterminal telopeptide of type I
collagen (ICTP) were measured using a two-antibody radio-
immunoassay (RIA) using Telopeptide ICTP RIA kits (Orion
Diagnostica, Espoo, Finland). ICTP is a peptide that is cleaved
during type I collagen degradation and was suggested to be a
marker of bone resorption (Risteli et al, 1993). The clinical
usefulness of measuring the serum concentrations of ICTP as a
marker for monitoring metastaic bone activity in patients with
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lprostate cancer was reported elsewhere (Noguchi and Noda,
2001). Normal ranges of serum ICTP were 1.8–5.0ngml
 1.
Alkaline phosphatase activity in serum was measured using p-
nitrophenyl phosphate substrate in diethanolamine buffer at 371C
with a normal range between 115 and 359IUl
 1. Tumour grade
was determined according to the Gleason scale (Gleason, 1977),
and classified as well-differentiated adenocarcinoma (Gleason
score 2–4), moderate (Gleason score 5–7) and poor (Gleason
score 8–10).
Bone scintigraphy
Tchnetium-99m-hydorxy-methane-diphosphonate (HMDP) bone
imaging was obtained after intravenous injection of Tc-99m
HMDP (555MBq, Nihon Mediphysics Co. Ltd, Japan). Bone
scintigraphy was obtained about 3h after intravenous injection
in all patients. Whole body images (scan speed 15cmmin
 1,
matrix 256 1024) were recorded with low energy, high-resolution
collimator E.CAM, Siemens Medical Systems, Inc.). The whole
body field was used to record anterior and posterior views digitally
(256 1024) on a detected computSer system (Toshiba 5500A/PI,
Tokyo, Japan). Energy discrimination was provided by a 10%
window centred on the 140keV of Tc-99m. All scans were
interpreted by one radiologist (MI) who was blinded to the
patient’s clinical condition, and the extent of metastatic bone
disease was determined according to the number of bone lesions
and the %PABS.
Numeric counting
The total number of lesions was determined by visual counting of
each discrete lesion using the method described previously
(Soloway et al, 1988), and the metastatic findings on bone scans
were classified into four groups in accordance with the EOD as
follows: grade 1, less than six bone metastases (a lesion occupy-
ing the entire vertebral body was counted as two lesions); grade
2, 6–20 bone metastases; grade 3, more than 20 bone metastases,
but less than a ‘super scan’ (diffuse symmetrical uptake without
visualisation of the kidneys); and grade 4, super scan or its
equivalent (involvement of greater than 75% of the ribs, vertebrae
and pelvic bones). The total number of lesions on the ‘super scan’
was counted as 100 in this study.
%PABS
To provide simply a quantitative measurement of the EOD,
the bone scans were analysed according to the following criteria.
All outlines of positive regions on a bone scan (both of anterior
and posterior scans) were transferred by tracing to a comprehen-
sive map of the entire bone metastasis. These findings were
converted to image files using a digitising pad and a drawing
program (MacPaint
s, Claris Corp., Santa Clara, CA, USA) with
a Macintosh computer (Apple, Inc., Cupertino, CA, USA)
(Figure 1B). The sum of all positive areas was automatically
measured using an image analysis program (NIH Image, developed
and maintained by the National Institutes of Health, Bethesda, MD,
USA) (Figure 1C). The fractional involvement of the entire
skeleton by metastasis was estimated as the %PABS. The %PABS
was calculated using the formula %PABS¼(positive area on
bone scan/square area) 100, in which the square area was
multiplied by the width at the gluteal region to the height of
the entire skeleton on the bone scan (Figure 1A). The %PABS
and number of bone lesions on five bone scans were measured by
five recorders to compare the accuracy and time consumption
of the %PABS method with the numeric counting. The coefficient
of variation (CV) was calculated by dividing the sample s.d. by the
sample mean. An average of five measurements were made for
each bone scan.
After obtaining a written informed consent, all 56 patients were
treated with luteinising hormone-releasing hormone agonist
(either goserelin acetate of leuprolide acetate) and an antiandrogen
agent (flutamide) or estramustine phosphate. Patients were
clinically evaluated monthly for the first 3 months, and every 3
months thereafter. Biochemical tests and physical examination
were repeated with the same frequency, while the chest film, bone
scan and the other instrumental examinations were repeated every
6 months unless specific symptoms occurred.
Figure 1 %PABS measurement. The %PABS is calculated using the formula %PABS¼(positive area on bone scan/square area) 100. (A) The estimated
square area is multiplied by the width at the gluteal region to the height of the entire skeleton on the bone scan. (B) Direct tracings of same hot spot
perimeters in B from the bone scan. (C) Computer tracings after measurement by NIH Image.
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lStatistical analysis
The baseline variables analysed in this study were age, Eastern
Cooperative Oncology Group (ECOG) performance status, PSA,
ICTP, alkaline phosphatase and %PABS. Correlation of the %PABS
with number of bone lesions was evaluated by a mean of Pearson’s
correlation coefficient test. The disease-specific survival was
determined by the Kaplan–Meier actuarial analysis, and the
difference between the disease-specific survival and survival curve
was assessed by the log-rank test. Cox proportional hazards
regression model was used for univariate and multivariate analyses
to identify factors that had a significant impact on survival. All
baseline parameters in the survival and proportional hazards
regression analysis were analysed as dichotomous variables using
the overall median values as cutoff levels. All statistical calculations
were carried out using the StatView
s program (SAS Institute Inc.,
Cary, NC, USA). A value of Po0.05 was considered statistically
significant.
RESULTS
In the initial analysis, the %PABS and number of bone lesions on
five kinds of bone scans were measured, and the results are shown
in Table 1. The CV in the %PABS ranged from 1.0 to 2.3% (mean,
1.54%), while the numeric counting ranged from 4.8 to 11.5%
(mean, 8.94%). The mean measuring time in both the %PABS and
the numeric counting was 16.6min (range, 15–20min) and 6.8min
(range, 5–8min), respectively.
The pretreatment clinical characteristics of the 56 patients are
listed in Table 2. The median age of the patient population was 72
years. A median of bone lesions per patient was 14. Of the 56 cases,
Table 1 Comparison between % PABS method and numeric counting
%PABS
a No. of bone lesions
b
Recorder BS
c-1 BS-2 BS-3 BS-4 BS-5
Measuring
time (min) BS-1 BS-2 BS-3 BS-4 BS-5
Measuring
time (min)
A 9.01 8.70 9.38 3.40 8.67 17 61 66 69 21 39 7
B 8.99 8.57 9.10 3.50 9.11 15 58 62 66 20 44 8
C 9.16 8.77 9.32 3.45 9.07 16 66 58 58 18 38 6
D 9.22 8.65 9.45 3.49 9.22 20 48 60 70 24 42 8
E 9.15 8.44 9.33 3.52 8.99 15 56 62 60 22 48 5
Mean 9.11 8.63 9.32 3.47 9.01 16.60 57.80 61.60 64.60 21.00 42.20 6.80
s.d.
d 0.10 0.13 0.13 0.05 0.21 2.07 6.65 2.97 5.37 2.24 4.03 1.30
CV
e (%) 1.10 1.50 1.40 1.40 2.30 12.50 11.50 4.80 8.30 10.60 9.50 19.20
aNIH Image computerised measurement.
bVisually counting.
cBone scintigraphy.
dStandard deviation.
eCoefficient of variation.
Table 2 Pretreatment clinical characteristics of the 56 study patients
EOD
Total Grade 1 Grade 2 Grade 3 Grade 4
No. of patients 56 15 22 15 4
Patient’s age (years)
Mean/median 72/72 72/74 72/72 71/71 70/71
Range 49–93 53–93 59–88 49–88 65–75
EOCG performance status
0+1 41 12 18 10 1
2+3 15 3 4 5 3
Biopsy grade
Well differentiated 7 4 1 2 0
Moderately differentiated 27 9 10 7 1
Poorly differentiated 22 2 11 6 3
PSA (ngml
 1)
Mean/median 425/220 144/112 321/171 517/296 1713/2000
Range 2–2000 14–561 2–1755 19–1967 853–2000
Alkaline phosphatase (IUl
 1)
Mean/median 635/467 343/233 499/357 1001/718 1101/774
Range 91–4751 118–1079 194–2334 91–4751 659–2197
ICTP (ngml
 1)
Mean/median 8.5/6.1 5.1/4.5 7.1/5.9 11.9/6.6 16.9/17.1
Range 1.9–52 2.5–8.5 1.9–26.5 4.3–52 11.2–22.2
No of bone lesions
Mean/median 23/14 4/4 13/12 38/30 100/100
Range 1–100 1–5 6–20 21–80 100–100
PABS (%)
Mean/median 7.7/4.6 1.6/0.9 4.0/3.6 14.1/12.8 26.7/23.3
Range 0.2–43.3 0.2–5.9 1.5–9.7 501–27.6 17.1–43.3
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l22 (39%) had EOD grade of 2, 15 (27%) had grade 1, 15 (27%)
grade 3 and only 4 (7%) grade 4. The median values for PSA,
alkaline phosphatase and ICTP increased with the extent of bone
metastasis. Figure 2 shows the linear regression analysis among the
%PABS measured using the NIH Image computer program and by
visual counting of the number of bone lesions. The %PABS well
correlated with the number of bone lesions with a higher
(R¼0.819 and R
2¼0.671; Po0.001) correlation in grade 1 and 2
patients (R¼0.732 and R
2¼0.536, Po0.001). The median %PABS
for the prostate cancer patients with bone metastasis sharply
increased as EOD grade progressed as follows: 0.9 for grade 1, 3.6
for grade 2, 12.8 for grade 3 and 23.3 for grade 4. Although %PABS
well correlated with EOD grade when examined as groups, there
were many overlaps in grading the bone metastasis in individual
patients (Figure 3).
A serial bone scan in a patient who showed improvement of
bone metastasis after hormonal therapy is shown in Figure 4. The
initial involvement in the bone slowly improved between 5
November 1996 and 24 February 1999 with a marked decrease in 50
40
30
20
10
0
−10
1 2 3 4
EOD grade
Pts. No. 15
Mean
Median
Range
1.6
0.9
0.2-5.9
22
4.0
3.6
1.5-9.7 5.1-27.6
15
14.1
12.8
4
26.7
23.3
17.1-43.3
%
P
A
B
S
Figure 2 Correlation between the %PABS and the number of bone
lesions.
50
40
30
20
10
0
−10
%
P
A
B
S
−10 0 10 20 30 40 50 60 70 80 90 100 110
No. of bone lesions
Figure 3 Correlation between the %PABS and the EOD grade from 1
to 4.
Figure 4 A serial bone scan in a patient who showed improvement of bone metastasis after hormonal therapy: (A) pretreatment; (B) 12 months after
treatment; (C) 27 months after treatment.
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l%PABS. However, it was difficult to count the accurate number of
multi bone lesions using the visual counting.
All patients received a hormonal therapy with various kinds of
regimen. The hormonal therapy included combined androgen
blockade (leuprolide plus flutamide or bicalutamide) (27 patients),
leuprolide plus estramustine phosphate (24 patients), flutamide
alone (three patients) and leuprolide alone (two patients). The
mean length of follow-up for all patients was 32 months (median,
29; range, 4–86), and 28 patients (50%) died because of prostate
cancer. The mean time to disease death was 27 months (median,
25; range, 4–50). The mean follow-up for those patients who did
not die because of prostate cancer was 36 months (median, 33;
range, 4–86). None of the patients were lost to follow-up during
this analysis. Only three out of eight patients who died of diseases
other than prostate cancer had an observation time shorter than 24
months (4, 10 and 12 months). Cox proportional hazards
regression analysis was performed to determine factors that would
predict the disease death (Table 3). In univariate regression
analysis, %PABS (P¼0.0155), serum alkaline phosphatase
(P¼0.0272), the tumour grade based on biopsy (P¼0.044) and
the number of bone lesions on bone scans (P¼0.0388) were
significantly associated with the disease-specific survival. Any of
the others studied (age, performance status, pretreatment PSA and
bone metabolic markers) were not significant factors. Forward
stepwise, multivariate analysis showed that only %PABS
(P¼0.0155, relative risk ratio 2.603) was an independent predictor
of the disease death. Patients with less than 4.6 %PABS had a
significantly better disease-specific survival compared with those
with greater than 4.6 %PABS (P¼0.011, Figure 5). All other
variables in Table 3 were insignificant predictors of the disease
death after hormonal treatment.
DISCUSSION
Radionuclide bone scans are strongly positive in cases of bone
involvement of prostate cancer patients, irrespective of whether
the lesions are radiologically lytic, mixed or pure blastic (Citrin
et al, 1981). The conventional method to monitor the response of
bone metastases to therapy is a combining qualitative assessment
of sequential bone scans and bony films with measurement of
chemical markers (such as PSA and alkaline phosphatase level).
Table 3 Cox proportional hazards regression analysis for 56 patients with prostate cancer with bone metastasis
Univariate Multivariate
Variable Cutoffs
a P-value
Relative
risk ratio 95% CI
b P-value
Relative
risk ratio
%PABS (%) 4.6 or greater/less than 4.6 0.016 2.603 1.199–5.651 0.016 2.603
Serum alkaline phosphatase (IUl
 1) 467 or greater/less than 467 0.027 2.452 1.016–5.434 FF
No. of bone lesions 14 or greater/less than 14 0.044 2.222 1.024–4.824 FF
Tumour grade on biopsy Poorly/well or moderately 0.044 2.153 1.021–4.540 FF
Serum ICTP (ngml
 1) 6.1 or greater/less than 6.1 0.103 1.906 0.878–4.136 FF
EOD grade 3 or 4/1or2 0.104 1.868 0.879–3.970 FF
Patient’s age (years) 72 or greater/less than 72 0.326 1.462 0.685–3.119 FF
Serum PSA (ngml
 1) 220 or greater/less than 220 0.361 1.430 0.664–3.079 FF
EOCG performance status 1 or 2 or 3/0 0.474 1.426 0.540–3.767 FF
a%PABS, alkaline phosphatase, number of bone lesions, ICTP, patient age and PSA are based on median values, and the remaining are treated as dichotomous
variables.
bConfidence intervals. Of the 56 patients, 28 (50%) had cancer death.
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Figure 5 Kaplan–Meier plot shows disease-specific survival after treatment of metastatic prostate cancer for those with less than 4.6 %PABS and greater
than 4.6 %PABS (P¼0.011).
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lHowever, to quantitate all bone metastases in patients is a time-
consuming task, since patients with metastatic involvement usually
have more than one disease site. Several studies have evaluated
different ways to quantify the extent of bone involvement during
therapy (Table 4). The EOD was graded into five categories by
visually counting the total number of bone lesions on the bone
scan (Soloway et al, 1988). This method has the difficulty of
counting individual lesions when lesions increase in number. It
was also recognised that errors would be inevitable because lesions
in the ribs are difficult to count and quantify, and assessment of
lesions in the pelvis is complicated by the three-dimensional
nature of the pelvic bone. In the present study, there was a weak
correlation between the %PABS measured using the NIH computer
program and the counted number of bone lesions in patients with
EOD grades 3 and 4 (greater than 21 bone metastases) compared
with grades 1 and 2 (less than 21 bone metastases). Other studies
have proposed staging classifications based on visual inspection,
whether the lesions on the bone scan occurred with normal uptake,
several uptakes or diffuse uptake (Amico et al, 1991), or according
to the negative versus positive (Chybowski et al, 1991). These
simplified grading systems showed significant associations with
survival (Crawford et al, 1989; Rana et al, 1993). It is, however,
difficult to evaluate serial changes on bone scans after treatment,
because the criteria for response and progression vary widely. A
simple and reproducible technique was evaluated to measure the
24-h whole body retention (skeletal uptakes) as an objective
marker for bony metastases in comparison to clinical outcome
(Dann et al, 1987). This method could be easily automated, but
much useful information such as the anatomical information,
about which bones are involved or progressing, was lost in this
simplified approach. As a result, none of these methods were
adopted into routine clinical practice. Some studies have devel-
oped a bone scan index (BSI) to more accurately quantify the
extent of the skeletal involvement by the tumour. This BSI method
is based on a subjective interpretation of the bone scan, in which
the fraction of each bone involved is visually estimated (Imbriaco
et al, 1998; Scabbatini et al, 1999). This technique is a complex
method to calculate the sum of the involved area in the 158 bones
by summing the fractions times the percentage of the skeleton for
each bone, and has shown a variation from 0 to 50% among
individual studies in the estimations. Techniques that use
computer generated regions of interest (ROI) for regional bone
uptake have been attempted in the BSI method (Erdi et al, 1997).
However, expense, long processing times and confusion relating to
the exact region to choose made this technique less than ideal.
In the present study, we used the NIH Image program for
measurements of all positive areas on bone scans transferred by
manual tracing to a comprehensive map. This method showed a
good accuracy for area measurements with a 1.54% CV. The main
advantages of the %PABS method are both its simplicity and
accuracy in measurements of ROI. However, although these
measures correlate with the extent of bone metastases in patients
with prostate cancer, the prognostic significance of these
measurements has not previously been demonstrated.
The conventional pretreatment risk factors for advanced
prostatic cancers were performance status, the presence or absence
of bone pain, tumour grade, biochemical parameters such as
haemoglobin, alkaline phosphatase and testosterone levels and the
EOD grade (Emrich et al, 1985; Soloway et al, 1988; Chodak et al,
1991). PSA is the most widely used tumour marker for diagnosis
and follow-up of prostate cancer, but the importance of pretreat-
ment PSA in predicting outcome after therapies was not yet
confirmed. In this study, we investigated the relation between
survival time and seven potential prognostic factors (age,
performance status, tumour grade, PSA, alkaline phosphatase,
ICTP and %PABS), using univariate and multivariate regression
models. The tumour grade, %PABS, alkaline phosphatase and
number of bone lesions were derived from a univariate analysis of
prognostic factors for the survival in this series, although the
tumour grade, alkaline phosphatase and the number of bone
lesions did not remain independent of prognostic value by
multivariate analysis. Only the %PABS was a significant predictor
of survival after hormonal treatments. Performance status, which
was reported as a very strong independent parameter previously
(Chodak et al, 1991), was not a significant predictor. One possible
reason for this discrepancy might be in part because of
heterogeneity of treatment in the present study. Although the
total number of patients in this study was small, the number of
patients who had disease death (26 patients, 50%) was quite high,
and makes the significance of the data from this study strong
relative to its size.
CONCLUSIONS
The findings of the present study suggest that the %PABS
quantified automatically using the NIH Image program is a simple
and reproducible estimate of the percentage of the skeleton
involving tumours in patients with advanced prostate cancer. This
method may be useful to stratify patients in clinical trials and may
provide prognostic information. A large-scaled trial with more
statistical power is needed to demonstrate that %PABS in patients
with prostate cancer with bone metastasis is a significant predictor
of survival after hormonal treatments. Further studies are required
to assess the utility of serial %PABS determination in monitoring
treatment effects.
Table 4 Definitions of grading systems for the extent of skeletal disease in prostate cancer using a bone scan
Reference Method Description
Soloway et al (1988) Visual inspection The total number of bone lesions were counted visually and graded into five
categories: 0, normal; 1, less than six lesions; 2, 6–20 lesions; 3, more than
20 lesions but not a superscan; 4, superscan.
Amico et al (1991) Visual inspection A bone scan scoring system from 0 to 2, 0 represents normal uptake, 1 means
one or several uptakes and 2 signifies diffuse uptake.
Chybowski et al (1991) Visual inspection A simple bone scan scoring system was similer to the above. This clasification
was negative, positive or indeterminate.
Dann et al (1987) Measurements of the total radiotracer uptake The 24-h whole body retention was measured as an objective marker for bone
metastasis.
Sabbatini et al (1999) Visual inspection A BSI was based on the known proportional weights of each of the 158 bones
that were derived from the reference man.
Erdi et al (1997) Computer analysis The images were transferred to a computer for ROI analysis and the BSI was
calculated.
Present study Visual and computer analysis The %PABS was quantified automatically using a computer with the NIH Image.
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